Keyphrases
Anti-PD-1
15%
Cancer Detection
17%
Cancer Patients
12%
Cell-free DNA (cfDNA)
100%
Cell-free DNA Analysis
12%
Circulating Tumor DNA (ctDNA)
79%
Clinical Response
12%
Computational Imaging
18%
DNA Fragmentation
32%
DNA Methylation (DNAm)
12%
Early Cancer
10%
Early Detection
24%
Fallopian Tube
10%
Genetic Modification
10%
Genetic mutation
10%
Genome-wide Investigation
10%
Glioblastoma
20%
Glioblastoma multiforme
21%
High-grade Serous Ovarian Cancer (HGSOC)
10%
Human Cancer
14%
Immune Cells
10%
Immune Checkpoint Blockade
21%
Immune Response
15%
In Cancer
15%
Liquid Biopsy
17%
Liver Cancer
13%
Lung Cancer
43%
Machine Learning Models
12%
Medulloblastoma
10%
Molecular Response
12%
Multiple Cancer Types
10%
Mutation Profiling
10%
Non-invasive Detection
35%
Non-small Cell Lung Cancer (NSCLC)
35%
Ovarian Cancer
27%
Overall Survival
16%
Patient Assessment
10%
Patients with Cancer
36%
Programmed Death-ligand 1 (PD-L1)
13%
Repeat Elements
10%
Signal Transducer and Activator of Transcription 3
10%
Single Molecule
10%
Somatic mutation
14%
Systemic Chemotherapy
10%
Targeted Therapy
10%
Tumor
32%
Tumor Immunity
10%
Tumor-immune System
10%
Ultrasensitive
12%
White Blood Cells
16%
Medicine and Dentistry
Adjuvant Chemotherapy
10%
Antigen Specificity
10%
Arm
10%
Biological Marker
28%
Brain Cancer
9%
Cancer Diagnosis
9%
Cancer Staging
10%
Cancer Therapy
13%
Carcinoma in Situ
10%
Cell Compartment
10%
Cell-Free DNA
68%
Circulating Tumor DNA
72%
Colon Carcinoma
10%
Colorectal Cancer
14%
Cost-Effectiveness Analysis
10%
CTLA-4
10%
Diagnosis
10%
Disease
13%
Epidermal Growth Factor Receptor
13%
Fallopian Tube
10%
Ganglioglioma
32%
Glioblastoma
9%
Hematopoiesis
8%
Immune Checkpoint Blockade
10%
Immune Response
12%
Immunocompetent Cell
11%
Immunotherapy
22%
Krukenberg Tumor
10%
Leukocyte
26%
Liquid Biopsy
22%
Liver Cancer
10%
Long Term Survival
21%
Lung Cancer
46%
Malignant Neoplasm
22%
Medulloblastoma
10%
Metastatic Colorectal Cancer
10%
Minimal Residual Disease
10%
Neoplasm
75%
Ovarian Cancer
20%
Overall Survival
17%
Pancreas Cancer
10%
Programmed Death-Ligand 1
12%
Radiation Therapy
12%
Receptor Blocking
10%
Recurrent Disease
11%
Stomach Cancer
10%
Symptom
10%
T Cell
12%
Targeted Therapy
13%
Treatment Response
17%